Filings & corporate actions
75 results filed
CSVNext results · Q2 FY27
Expected 10 Nov 2026 – 15 Nov 2026
Estimate: filed 41–46 days after quarter end, last 5 times
Dividend
₹0.05 per share · last 11 Sept 2020
2026
- 14 AugresultsResults · Q1 FY27 · consolidated and standalone+2.1%NSE
- 13 JulshareholdingShareholding · 30 Jun 2026-0.9%NSE
- 30 MayresultsResults · Q4 FY26 · consolidated and standalone-2.9%NSE
- 9 AprshareholdingShareholding · 31 Mar 2026-0.9%NSE
- 29 JanshareholdingShareholding · 20 Jan 2026-1.1%NSE
- 23 JanresultsResults · Q3 FY26 · consolidated and standalone-4.6%NSE
- 6 JanshareholdingShareholding · 31 Dec 2025+1.9%NSE
Reaction to results · all yearsrose on day 0 in 26 of 75 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q1 FY27 | 14 Aug 2026 | +2.1% | -2.5% | +3.6% | 2.0× |
| Q4 FY26 | 30 May 2026 | -2.9% | -6.5% | -7.1% | 0.5× |
| Q3 FY26 | 23 Jan 2026 | -4.6% | -5.1% | -13.4% | 0.6× |
| Q2 FY26 | 14 Nov 2025 | -1.0% | -4.3% | +42.4% | 1.6× |
| Q1 FY26 | 14 Aug 2025 | +4.1% | +6.2% | +17.0% | 0.5× |
| Q4 FY25 | 8 Jul 2025 | -20.0% | -22.5% | -36.1% | 20.8× |
| Q3 FY25 | 31 Jan 2025 | +5.0% | +11.9% | -24.8% | 0.4× |
| Q2 FY25 | 14 Nov 2024 | +2.0% | -4.7% | +17.6% | 11.0× |
| Q1 FY25 | 14 Aug 2024 | -1.0% | +20.7% | +73.3% | 0.7× |
| Q4 FY24 | 15 May 2024 | -4.3% | -6.7% | -7.1% | 1.1× |
| Q3 FY24 | 14 Feb 2024 | +0.5% | +13.0% | -13.4% | 0.7× |
| Q2 FY24 | 10 Nov 2023 | +7.1% | +7.1% | +20.9% | 16.2× |
| Q1 FY24 | 14 Aug 2023 | +0.2% | +3.2% | +3.2% | 0.5× |
| Q4 FY23 | 26 May 2023 | -1.7% | +0.6% | +9.0% | 1.0× |
| Q3 FY23 | 14 Feb 2023 | -0.5% | -7.0% | -12.4% | 0.5× |
| Q2 FY23 | 15 Nov 2022 | -3.3% | -6.8% | +9.1% | 2.2× |
| Q1 FY23 | 13 Aug 2022 | -2.0% | -7.3% | +2.9% | 1.4× |
| Q4 FY22 | 30 May 2022 | +3.1% | -3.3% | -8.9% | 1.4× |
| Q3 FY22 | 14 Feb 2022 | +4.0% | -9.0% | -9.8% | 0.5× |
| Q2 FY22 | 13 Nov 2021 | -1.9% | -4.5% | +5.0% | 0.9× |
| Q1 FY22 | 14 Aug 2021 | -3.2% | -6.1% | -0.5% | 0.8× |
| Q4 FY21 | 23 Jul 2021 | -4.5% | -12.6% | -27.4% | 0.8× |
| Q3 FY21 | 13 Feb 2021 | -4.7% | -2.9% | 0.0% | 2.6× |
| Q2 FY21 | 30 Oct 2020 | -6.2% | -15.7% | +9.5% | 1.5× |
| Q1 FY21 | 1 Oct 2020 | -5.5% | -3.4% | -17.3% | 1.5× |
| Q4 FY20 | 29 Jul 2020 | -9.8% | -2.2% | +4.9% | 1.7× |
| Q3 FY20 | 11 Feb 2020 | -2.2% | -5.6% | -32.2% | 0.8× |
| Q2 FY20 | 14 Nov 2019 | -14.4% | -10.1% | -17.4% | 3.0× |
| Q1 FY20 | 14 Aug 2019 | -6.1% | -16.0% | -6.7% | 1.4× |
| Q4 FY19 | 25 May 2019 | +19.8% | +9.2% | -11.5% | 32.6× |
| Q3 FY19 | 19 Feb 2019 | +0.3% | +3.1% | +13.5% | 0.3× |
| Q2 FY19 | 27 Nov 2018 | -1.0% | -2.9% | -3.6% | 0.7× |
| Q1 FY19 | 20 Aug 2018 | -1.3% | +21.2% | +8.8% | 0.7× |
| Q4 FY18 | 21 Jun 2018 | -2.4% | -11.2% | -22.3% | 0.5× |
| Q3 FY18 | 14 Feb 2018 | -2.9% | -5.9% | -9.7% | 0.5× |
| Q2 FY18 | 22 Nov 2017 | +7.5% | +2.3% | +15.7% | 3.8× |
| Q1 FY18 | 1 Sept 2017 | +5.9% | +3.4% | +0.9% | 1.6× |
| Q4 FY17 | 27 Jun 2017 | -3.1% | -0.2% | -1.2% | 0.8× |
| Q3 FY17 | 17 Feb 2017 | +1.8% | -0.5% | -3.0% | 1.6× |
| Q2 FY17 | 16 Dec 2016 | -1.5% | -8.5% | -3.9% | 5.1× |
| Q1 FY17 | 20 Sept 2016 | -2.1% | +2.9% | -5.6% | 0.6× |
| Q4 FY16 | 30 May 2016 | -6.5% | -10.4% | -6.7% | 1.7× |
| Q3 FY16 | 9 Feb 2016 | -3.1% | -13.3% | -4.2% | 0.4× |
| Q2 FY16 | 13 Nov 2015 | -4.9% | +0.6% | +5.7% | 0.5× |
| Q1 FY16 | 14 Aug 2015 | -0.6% | -5.9% | -5.4% | 0.7× |
| Q4 FY15 | 29 May 2015 | -0.9% | -8.4% | -6.5% | 0.5× |
| Q3 FY15 | 18 Feb 2015 | -0.3% | -17.0% | +25.4% | 0.3× |
| Q2 FY15 | 21 Nov 2014 | -4.2% | -10.7% | -20.0% | 0.5× |
| Q1 FY15 | 18 Aug 2014 | +5.3% | +43.0% | +48.3% | 1.7× |
| Q4 FY14 | 28 May 2014 | -1.1% | +6.0% | +4.8% | 0.6× |
| Q3 FY14 | 11 Feb 2014 | -2.8% | -7.4% | +12.3% | 0.5× |
| Q2 FY14 | 25 Nov 2013 | -0.6% | +1.5% | +4.4% | 0.4× |
| Q1 FY14 | 17 Aug 2013 | -5.5% | +2.7% | +8.2% | 1.4× |
| Q4 FY13 | 18 May 2013 | -4.5% | -13.4% | -9.2% | 1.1× |
| Q3 FY13 | 19 Feb 2013 | +0.9% | -1.5% | +11.2% | 0.3× |
| Q2 FY13 | 1 Nov 2012 | +5.0% | +14.4% | +20.8% | 1.7× |
| Q1 FY13 | 11 Aug 2012 | 0.0% | +7.0% | +23.3% | 0.2× |
| Q4 FY12 | 14 May 2012 | -6.0% | -11.4% | -9.4% | 0.9× |
| Q3 FY12 | 10 Feb 2012 | +9.3% | +7.2% | +2.8% | 4.6× |
| Q2 FY12 | 12 Nov 2011 | -3.3% | -8.1% | -11.7% | 0.6× |
| Q1 FY12 | 17 Aug 2011 | -0.5% | -5.5% | +3.0% | 1.4× |
| Q4 FY11 | 12 May 2011 | +1.1% | -9.9% | -0.4% | 2.1× |
| Q3 FY11 | 14 Jan 2011 | -4.6% | -1.6% | -13.0% | 1.8× |
| Q2 FY11 | 8 Nov 2010 | -4.1% | -4.8% | -23.1% | 1.9× |
| Q1 FY11 | 11 Aug 2010 | -3.2% | -1.1% | +1.1% | 1.3× |
| Q3 FY10 | 12 Jan 2010 | +2.3% | +3.9% | -7.3% | 7.6× |
| Q2 FY10 | 20 Oct 2009 | +5.0% | +9.9% | +14.3% | 4.1× |
| Q1 FY10 | 24 Jul 2009 | -0.5% | +2.5% | +4.9% | 1.1× |
| Q3 FY09 | 31 Jan 2009 | -11.6% | -14.5% | -24.1% | 3.1× |
| Q2 FY09 | 31 Oct 2008 | +20.0% | +40.7% | +13.0% | 1.6× |
| Q1 FY09 | 28 Jul 2008 | -1.0% | +5.5% | +13.3% | 0.4× |
| Q3 FY08 | 28 Jan 2008 | +2.6% | +2.8% | -7.2% | 0.7× |
| Q2 FY08 | 30 Oct 2007 | +5.9% | +0.8% | +2.6% | 3.5× |
| Q1 FY08 | 30 Jul 2007 | +4.4% | +3.7% | +4.8% | 0.7× |
| Q4 FY07 | 30 Apr 2007 | +3.3% | -7.1% | -8.0% | 1.1× |
| Average | -0.7% | -1.2% | +0.4% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q1 FY27
CSVRevenue YoY-100.0%
Profit YoY—
Interest cost YoY-50.5%
Revenue QoQ—
Profit QoQ—
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | -94.5% | -85.1% | -76.7% | -68.2% | -63.7% | — |
| Profit | — | — | — | — | — | — |
Key data
CSVOpen10.62
Day range10.30 – 11.00
52-week range9.30 – 22.40
From 52w high-51.1%
RSI (14)48.2
ATR (14)0.54
Volume3.36L
Avg volume (20D)1.46L
Rel volume2.30×
Volatility (1Y)52.3%
Turnover₹36.8L
SMA 50 / 20011.11 / 12.67
Delivery percentage
Latest · 6 Oct 202697.4%
20-day avg74.9%
1-year avg86.8%
Percentile (own history)83rd
Range17.4–100.0%
Sessions1,731
Over the last 20 sessions NECLIFE settled 74.9% of its traded quantity, which is unusually high for an NSE equity. Its one-year average is 86.8%, so recent sessions are running 11.8 points lower than usual. The latest session ranks higher than 83% of the 1,731 sessions on record for it.
What delivery percentage measuresScan the whole market on delivery
IndustryPharmaceuticals
Performance returns
CSV| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +4.48% | +2.15% | -10.02% | -2.41% | +9.06% | -24.06% |
Valuation
CSVMarket cap₹213 Cr
P/E (TTM)—
EPS (TTM)-12.61
Shares outstanding19.43Cr
Listed18 Jul 2005
Ownership
CSVPromoter51.84%
Promoter Δ QoQ0.00 pp
Public48.16%
FII0.50%
DII3.74%
Pledged0.00%
Quarterly results · consolidated
CSV| Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 5.0 | 0.0 | 0.0 | 0.0 |
| YoY chg | -98.8% | -100.0% | -100.0% | -100.0% |
| Net profit (₹ Cr) | (176.0) | 14.3 | (67.9) | (15.4) |
| YoY chg | -3243.6% | +82.0% | — | — |
| Net margin | -3522.5% | — | — | -106191.0% |
| EPS | -7.84 | 0.64 | -3.38 | -0.79 |
Shareholding over time
CSVBy quarter
30 Jun 2026 · promoter 51.84% · public 48.16%2021-092026-06
- Promoter
- Public and others
- Promoter
- 51.84%
- Public
- 48.16%
- Promoter change
- 0.00 pp
- Filed
- 13 Jul 2026
- FII
- 0.50%
- DII
- 3.74%
- Promoter pledged
- 0.00%
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional and pledge figures come from a separate filing stage whose backfill is still running, so they are absent for almost every instrument rather than zero.
Financials · quarterly statement
CSV₹ crore, as filed
| Q2 FY24 | Q3 FY24 | Q4 FY24A | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25A | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26A | Q1 FY27 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue from operations | 398.0 | 452.2 | 441.4 | 359.3 | 428.1 | 455.0 | 430.7 | 280.7 | 5.0 | 0.0 | 0.0 | 0.0 | |
| Other income | 10.6 | 0.5 | 1.5 | 0.6 | 0.7 | 0.6 | 0.1 | 0.3 | 0.7 | 0.7 | 7.6 | 3.3 | |
| Total income | 408.6 | 452.7 | 442.8 | 359.9 | 428.8 | 455.6 | 430.8 | 281.0 | 5.7 | 0.7 | 7.6 | 3.4 | |
| Total expenses | 406.9 | 450.2 | 431.7 | 354.9 | 420.1 | 443.0 | 618.4 | 377.8 | 6.2 | 32.2 | 64.5 | 28.0 | |
| └ Finance costs | 20.5 | 24.8 | 24.2 | 20.0 | 19.8 | 17.1 | 17.7 | 18.7 | 0.0 | 30.2 | 5.9 | 0.2 | |
| └ Depreciation | 15.3 | 15.4 | 14.7 | 15.5 | 15.5 | 15.6 | 15.8 | 16.5 | 0.2 | 0.1 | 0.1 | 0.1 | |
| Profit before tax | 1.6 | 2.5 | 11.1 | 4.9 | 8.7 | 12.5 | (187.7) | (96.8) | (0.5) | 56.6 | (56.9) | (24.6) | |
| Tax expense | 0.6 | 0.9 | 10.5 | 1.9 | 3.1 | 4.7 | (57.6) | (33.5) | (0.2) | (11.0) | (19.7) | (8.9) | |
| Net profit | 1.0 | 1.6 | 0.6 | 3.0 | 5.6 | 7.8 | (130.1) | (63.2) | (176.0) | 14.3 | (67.9) | (15.4) | |
| EPS | 0.05 | 0.07 | 0.03 | 0.13 | 0.25 | 0.35 | -5.80 | -2.82 | -7.84 | 0.64 | -3.38 | -0.79 | |
| Net margin | 0.26% | 0.35% | 0.13% | 0.83% | 1.31% | 1.72% | -30.20% | -22.53% | -3522.51% | — | — | -106191.03% | |
| PBT margin | 0.41% | 0.54% | 2.52% | 1.37% | 2.02% | 2.76% | -43.57% | -34.47% | -10.13% | — | — | -169789.66% | |
| Tax rate | 38.15% | 36.21% | 94.67% | 39.62% | 35.39% | 37.52% | — | — | — | -19.48% | — | — |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. A quarterly filing carries a profit and loss only — there is no balance sheet behind it, and so no debt, cash flow or return-on-capital figure here. Latest filed 14 Aug 2026.
NECLIFE at a glance
- NECLIFE closed at ₹10.95 on 6 Oct 2026, +4.48% on the day, -24.1% over one year, 51.1% below its 52-week high of ₹22.4.
- Delivery was 97.4% of traded quantity on 6 Oct 2026, the 83rd percentile of its own 1,731 sessions with a reading (20-session average 74.9%, 1-year average 86.8%).
- Market capitalisation is ₹213 crore, with no positive trailing earnings for a P/E (trailing EPS ₹-12.61).
- Q1 FY27 results (consolidated, filed 14 Aug 2026): revenue ₹0 crore (-100.0% year on year), net profit ₹-15 crore; the price moved +2.1% on the first session after.
- Promoters held 51.84% at 30 Jun 2026, unchanged on the previous filing.
- Q2 FY27 results are expected between 10 Nov 2026 and 15 Nov 2026, going by past filing dates — an estimate, not an announcement.
About
CSVMacro sectorHealthcare
Basic industryPharmaceuticals
ISININE023H01027
SeriesEQ
Listed18 Jul 2005
History from18 Jul 2005
Sessions5,256
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 6 Oct 2026.
More in Pharmaceuticals & Biotechnology
CSV- DIVISLABDivi's Laboratories Limited9,550.00+3.85%
- LAURUSLABSLaurus Labs Limited2,050.00+3.99%
- SUNPHARMASun Pharmaceutical Industries Limited1,804.10+1.37%
- WOCKPHARMAWockhardt Limited2,176.40+5.47%
- DRREDDYDr. Reddy's Laboratories Limited1,208.00+0.42%
- MOREPENLABMorepen Laboratories Limited143.96+6.41%
- ZYDUSLIFEZydus Lifesciences Limited1,159.50+1.80%
- SYMBIOTECSYMBIOTEC1,149.50-1.73%
- TORNTPHARMTorrent Pharmaceuticals Limited4,772.000.00%
- GLANDGland Pharma Limited3,006.10+3.25%
- LUPINLupin Limited2,029.30+0.91%
- AUROPHARMAAurobindo Pharma Limited1,692.80+1.07%
All Pharmaceuticals & Biotechnology stocks on the NSEAll Healthcare stocks on the NSE